The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, however its future within the broader sector now raises questions about long-term yields . Copycat versions are eroding exclusivity , leading to anxieties that investing in companies closely tied to Viagra's once-dominant position could be a problematic decis